The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.
 
Manuel M. Hidalgo
Honoraria - BioLineRx
Consulting or Advisory Role - BioLineRx
Research Funding - BioLineRx
 
Ron Epelbaum
Research Funding - BioLineRx (Inst)
 
Valeriya Semenisty
No Relationships to Disclose
 
Ravit Geva
Research Funding - BioLineRx (Inst)
 
Talia Golan
Consulting or Advisory Role - BioLineRx
Research Funding - BioLineRx (Inst)
 
Erkut Hasan Borazanci
Consulting or Advisory Role - Bayer; Biogen (I); Fujifilm; Genzyme (I); Merrimack; Novartis (I); Teva (I)
Speakers' Bureau - Biogen (I); Genzyme (I); Ipsen; Merrimack; Novartis (I); Taiho Pharmaceutical; Teva (I)
 
Salomon M. Stemmer
Research Funding - BioLineRx (Inst)
 
Mitesh J. Borad
Stock and Other Ownership Interests - Gilead Sciences; GlaxoSmithKline
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); Fujifilm (Inst); G1 Therapeutics; Halozyme (Inst); Inspyr Therapeutics; Insys Therapeutics (Inst); Novartis (Inst); TD2
Research Funding - Agios (Inst); ARIAD (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun BioPharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Joon Oh Park
Honoraria - Celgene
Consulting or Advisory Role - Celgene
Speakers' Bureau - Celgene; Celgene; Celgene
Research Funding - AstraZeneca; Celgene
 
Katrina Pedersen
Speakers' Bureau - Clinical Care Options
 
Brian M. Wolpin
Consulting or Advisory Role - Genentech
 
Robert A. Ramirez
Research Funding - BioLineRx (Inst)
 
Carlos Becerra
Honoraria - Taiho Pharmaceutical
Consulting or Advisory Role - SOBI
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Taiho Pharmaceutical
 
Stephen Michael Shaw
Employment - BioLineRx
 
Galia Oberkovitz
Employment - BioLineRx
 
Ella Sorani
Employment - BioLineRx
 
Tzipora M Lustig
Employment - BioLineRx
 
Abi Vainstein Haras
Employment - BioLineRx
 
Amnon Peled
Employment - Biokine Therapuetics
Consulting or Advisory Role - BioLineRx
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Anthem Inc; Capella Therapeutics; Cell Therapeutics; CerRx; McKesson; Medtronic; Stromatis Pharma; SynDevRx; Systems Oncology; UnitedHealthcare
Honoraria - Celgene
Consulting or Advisory Role - 2X Oncology; 7 Hills Pharma; AADi; Actinium Pharmaceuticals; Aduro Biotech; Aeglea Biotherapeutics; Alethia Biotherapeutics; Alpha Cancer Technologies; Aptose Biosciences; Araxes Pharma; ARIAD; ARMO BioSciences; Arvinas; Athenex; Bellicum Pharmaceuticals; BeyondSpring Pharmaceuticals; Bicycle Therapeutics; BiolineRx; Bionomics; Boston Biomedical; Bristol-Myers Squibb; CanBas; Cancer Prevention Pharmaceuticals; Cerulean Pharma; CORRONA; CV6 Therapeutics; CytomX Therapeutics; Deciphera; Defined Health; DNAtrix; EMD Serono; Esperance Pharmaceuticals; Evelo Therapeutics; Fate Therapeutics; FibroGen; Five Prime Therapeutics; FORMA Therapeutics; Formula Pharmaceuticals; Fujifilm; Geistlich Pharma; Genzada Pharmaceuticals; Gilead Sciences; Histogen; Horizon Discovery; Horizon Pharma; HUYA Bioscience International; Idera; Ignyta; Imaging Endpoints; Immodulon Therapeutics; Immunophotonics; Innate Pharma; Innokeys; Insys Therapeutics; Intezyne Technologies; Ipsen; Janssen Diagnostics; Jounce Therapeutics; Kalos Therapeutics; Kura Oncology; L.E.A.F. Pharmaceuticals; Lilly; Lixte Biotechnology; MBC Pharma; Medical Prognosis Institute; miRNA Therapeutics; Novita Pharmaceuticals; Novocure; Nucana; Oncology Venture; Oncolytics; Oncolyze; Orphagen Pharmaceuticals; Pain Therapeutics; Pharmamab; Phosplatin Therapeutics; Reflexion Medical; RenovoRx; Samus Therapeutics; SciClone; Senhwa Biosciences; SOTIO; Strategia Therapeutics; Sumitomo Dainippon; Sun Biopharma; Synergene; Systems Imagination; TargaGenix; Tavistock Life Sciences; TD2; Tolero Pharmaceuticals; TP Therapeutics; Trovagene; Ventana Medical Systems; Verily; Vertex; Viamet Pharmaceuticals
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Aduro Biotech (Inst); Agios (Inst); ArQule (Inst); Baxalta (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); ESSA (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); miRNA Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Samumed (Inst); Strategia (Inst); Trovagene (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer